ECOR — electroCore, Inc.

Summary of electroCore, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $9.6 million, a 43% increase year-over-year, marking the highest revenue quarter in the company's history.
• Gross Margin: Expanded to 87%, a 200 basis point improvement from the previous year.
• GAAP Net Loss: $5.3 million, compared to $3.9 million in Q1 2025, primarily due to $1.9 million in nonrecurring leadership transition costs.
• Adjusted EBITDA Loss: Improved by 24% to $2.3 million from $3.1 million year-over-year.
• Cash Position: Approximately $8.8 million in cash and equivalents as of March 31, 2026, down from $11.6 million at the end of 2025.

2. Strategic Updates and Business Highlights

• Leadership Transition: The company is undergoing a leadership transition with Joshua Lev as interim president and Mike Fox as the new COO, focusing on operational discipline and growth in federal channels.
• VA Market Penetration: Revenue from VA prescription devices grew 48% to $7.9 million, with gammaCore and Quell products gaining traction. Approximately 15,000 VA patients have received gammaCore, representing about 2.5% penetration of the addressable VA headache market.
• Consumer Wellness Channel: Revenue reached $1.6 million, up 44% year-over-year, driven by TruVega, which saw improved return on advertising spend (ROAS) of 2.37.
• TACSTIM Product: Demand for TACSTIM in military channels is increasing, with ongoing research and evaluation in various military commands.

3. Forward Guidance and Outlook

• Full-Year 2026 Revenue Guidance: The company reaffirmed guidance for approximately 30% growth, expecting $9 million to $10 million in incremental revenue compared to 2025.
• Growth Catalysts: Focus on expanding clinical evidence, penetrating additional commercial channels, and enhancing operational efficiencies to support profitability.

4. Challenges and Points of Concern

• Increased Net Loss: The GAAP net loss widened due to leadership transition costs, raising concerns about cost management during the transition.
• Cash Burn: Q1 is typically the highest cash burn quarter, and there may be extended cash burn into Q2 due to inventory and capital improvements.
• Market Penetration: While there is significant room for growth in the VA market, the current penetration rate is low, indicating a need for more effective strategies to increase utilization.

5. Notable Q&A Insights

• Sales Strategy: Mike Fox emphasized the importance of deepening relationships within the VA and federal channels, focusing on increasing prescriber engagement rather than merely expanding the number of facilities.
• Kaiser Permanente: Discussions are ongoing to leverage key opinion leaders within Kaiser to drive product adoption.
• TruVega Marketing: The shift towards affiliate and influencer marketing has improved ROAS, indicating a strategic pivot in marketing efforts.
• FDA Discussions: Ongoing efforts to aggregate data for a potential PTSD label are in progress, with the company actively engaging with the FDA to expand the Breakthrough designation.

Overall, electroCore, Inc. demonstrated strong revenue growth and operational improvements in Q1 2026, while also navigating leadership changes and focusing on strategic market penetration. The company remains optimistic about its growth trajectory despite some challenges related to cash management and market saturation.